ANAB AnaptysBio Inc.

10.38
+0.2  (+2%)
Previous Close 10.18
Open 10.3
Price To Book 0.63
Market Cap 280,754,046
Shares 27,047,596
Volume 4,522,754
Short Ratio
Av. Daily Volume 671,742
Stock charts supplied by TradingView

NewsSee all news

  1. AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates

    Topline Data From Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Failed to Meet Primary EndpointReported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of

  2. AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

    SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation,

  3. AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

    Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy studyBoth patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring

  4. AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference

    SAN DIEGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data failed to meet primary endpoint - November 8, 2019.
ANB020 - etokimab
Moderate-to-severe adult atopic dermatitis
Phase 2b trial initiation postponed.
ANB020 - etokimab
Severe adult eosinophilic asthma
Phase 2 data due 1H 2020.
ANB019
Palmo-plantar pustular psoriasis
Phase 2 interim data on first TWO patients announced September 30, 2019 with patients reaching primary endpoint. Further data due 2020.
ANB019
Generalized pustular psoriasis
Phase 2 data due 1Q 2020.
ANB020 - etokimab
Nasal polyps

Latest News

  1. AnaptysBio Announces Third Quarter 2019 Financial Results and Provides Pipeline Updates

    Topline Data From Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Failed to Meet Primary EndpointReported Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of

  2. AnaptysBio Reports Etokimab ATLAS Phase 2b Clinical Trial in Moderate-to-Severe Atopic Dermatitis Fails to Meet Primary Endpoint

    SAN DIEGO, Nov. 08, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation,

  3. AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

    Interim analysis conducted with first two patients to complete 16-week (Day 113) ANB019 monotherapy studyBoth patients achieved the primary endpoint of disease score improvement at Day 29 and Day 113 without requiring

  4. AnaptysBio to Present at the Cantor Fitzgerald Global Healthcare Conference

    SAN DIEGO, Sept. 27, 2019 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (NASDAQ:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation,